Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Antitumor immune response during glioma virotherapy.

Youssef GC, Gomez-Manzano C, Sawaya R, Fueyo J.

Neuro Oncol. 2019 Jul 26. pii: noz114. doi: 10.1093/neuonc/noz114. [Epub ahead of print] No abstract available.

PMID:
31348516
2.

Immune Suppression during Oncolytic Virotherapy for High-Grade Glioma; Yes or No?

Koks CA, De Vleeschouwer S, Graf N, Van Gool SW.

J Cancer. 2015 Jan 15;6(3):203-17. doi: 10.7150/jca.10640. eCollection 2015. Review.

3.

The therapeutic efficacy of the oncolytic virus Delta24-RGD in a murine glioma model depends primarily on antitumor immunity.

Kleijn A, Kloezeman J, Treffers-Westerlaken E, Fulci G, Leenstra S, Dirven C, Debets R, Lamfers M.

Oncoimmunology. 2014 Dec 13;3(9):e955697. eCollection 2014 Oct.

4.

Deficiency of the IRE1α-Autophagy Axis Enhances the Antitumor Effects of the Oncolytic Virus M1.

Li K, Hu C, Xing F, Gao M, Liang J, Xiao X, Cai J, Tan Y, Hu J, Zhu W, Yin W, Li Y, Chen W, Lu B, Mai J, Qiu P, Su X, Yan G, Zhang H, Lin Y.

J Virol. 2018 Feb 26;92(6). pii: e01331-17. doi: 10.1128/JVI.01331-17. Print 2018 Mar 15.

5.

Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death.

Koks CA, Garg AD, Ehrhardt M, Riva M, Vandenberk L, Boon L, De Vleeschouwer S, Agostinis P, Graf N, Van Gool SW.

Int J Cancer. 2015 Mar 1;136(5):E313-25. doi: 10.1002/ijc.29202. Epub 2014 Sep 19.

6.

Oncolytic virotherapy for malignant glioma: translating laboratory insights into clinical practice.

Auffinger B, Ahmed AU, Lesniak MS.

Front Oncol. 2013 Feb 25;3:32. doi: 10.3389/fonc.2013.00032. eCollection 2013.

7.

The role of TNF-α inhibitor in glioma virotherapy: A mathematical model.

Ratajczyk E, Ledzewicz U, Leszczynski M, Friedman A.

Math Biosci Eng. 2017 Feb 1;14(1):305-319. doi: 10.3934/mbe.2017020.

8.

Cellular factors promoting resistance to effective treatment of glioma with oncolytic myxoma virus.

Zemp FJ, McKenzie BA, Lun X, Reilly KM, McFadden G, Yong VW, Forsyth PA.

Cancer Res. 2014 Dec 15;74(24):7260-73. doi: 10.1158/0008-5472.CAN-14-0876. Epub 2014 Oct 21.

9.

CRAdRGDflt-IL24 virotherapy in combination with chemotherapy of experimental glioma.

Kaliberova LN, Krendelchtchikova V, Harmon DK, Stockard CR, Petersen AS, Markert JM, Gillespie GY, Grizzle WE, Buchsbaum DJ, Kaliberov SA.

Cancer Gene Ther. 2009 Oct;16(10):794-805. doi: 10.1038/cgt.2009.23. Epub 2009 Apr 10.

10.

A Comparative Study of Replication-Incompetent and -Competent Adenoviral Therapy-Mediated Immune Response in a Murine Glioma Model.

Kim JW, Miska J, Young JS, Rashidi A, Kane JR, Panek WK, Kanojia D, Han Y, Balyasnikova IV, Lesniak MS.

Mol Ther Oncolytics. 2017 May 6;5:97-104. doi: 10.1016/j.omto.2017.05.001. eCollection 2017 Jun 16.

11.

VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells.

Currier MA, Eshun FK, Sholl A, Chernoguz A, Crawford K, Divanovic S, Boon L, Goins WF, Frischer JS, Collins MH, Leddon JL, Baird WH, Haseley A, Streby KA, Wang PY, Hendrickson BW, Brekken RA, Kaur B, Hildeman D, Cripe TP.

Mol Ther. 2013 May;21(5):1014-23. doi: 10.1038/mt.2013.39. Epub 2013 Mar 12.

12.

Virotherapy-recruited PMN-MDSC infiltration of mesothelioma blocks antitumor CTL by IL-10-mediated dendritic cell suppression.

Tan Z, Liu L, Chiu MS, Cheung KW, Yan CW, Yu Z, Lee BK, Liu W, Man K, Chen Z.

Oncoimmunology. 2018 Oct 16;8(1):e1518672. doi: 10.1080/2162402X.2018.1518672. eCollection 2019.

PMID:
30546960
13.

Antitumor virotherapy using syngeneic or allogeneic mesenchymal stem cell carriers induces systemic immune response and intratumoral leukocyte infiltration in mice.

Morales-Molina Á, Gambera S, Cejalvo T, Moreno R, Rodríguez-Milla MÁ, Perisé-Barrios AJ, García-Castro J.

Cancer Immunol Immunother. 2018 Oct;67(10):1589-1602. doi: 10.1007/s00262-018-2220-2. Epub 2018 Jul 31.

PMID:
30066102
14.

Healing after death: antitumor immunity induced by oncolytic adenoviral therapy.

Jiang H, Fueyo J.

Oncoimmunology. 2014 Jul 3;3(7):e947872. eCollection 2014.

15.

Oncolytic virotherapy for human malignant mesothelioma: recent advances.

Boisgerault N, Achard C, Delaunay T, Cellerin L, Tangy F, Grégoire M, Fonteneau JF.

Oncolytic Virother. 2015 Sep 10;4:133-40. doi: 10.2147/OV.S66091. eCollection 2015. Review.

16.

Interferon-β sensitivity of tumor cells correlates with poor response to VA7 virotherapy in mouse glioma models.

Ruotsalainen J, Martikainen M, Niittykoski M, Huhtala T, Aaltonen T, Heikkilä J, Bell J, Vähä-Koskela M, Hinkkanen A.

Mol Ther. 2012 Aug;20(8):1529-39. doi: 10.1038/mt.2012.53. Epub 2012 Mar 20.

17.

[Oncolytic viruses for therapy of malignant glioma].

Sosnovtceva AO, Grinenko NF, Lipatova AV, Chumakov PM, Chekhonin VP.

Biomed Khim. 2016 May;62(4):376-90. doi: 10.18097/PBMC20166204376. Review. Russian.

PMID:
27562991
18.

The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models.

Martínez-Vélez N, Garcia-Moure M, Marigil M, González-Huarriz M, Puigdelloses M, Gallego Pérez-Larraya J, Zalacaín M, Marrodán L, Varela-Guruceaga M, Laspidea V, Aristu JJ, Ramos LI, Tejada-Solís S, Díez-Valle R, Jones C, Mackay A, Martínez-Climent JA, García-Barchino MJ, Raabe E, Monje M, Becher OJ, Junier MP, El-Habr EA, Chneiweiss H, Aldave G, Jiang H, Fueyo J, Patiño-García A, Gomez-Manzano C, Alonso MM.

Nat Commun. 2019 May 28;10(1):2235. doi: 10.1038/s41467-019-10043-0.

19.

Intratumoral oncolytic adenoviral treatment modulates the glioma microenvironment and facilitates systemic tumor-antigen-specific T cell therapy.

Qiao J, Dey M, Chang AL, Kim JW, Miska J, Ling A, M Nettlebeck D, Han Y, Zhang L, Lesniak MS.

Oncoimmunology. 2015 Apr 2;4(8):e1022302. eCollection 2015 Aug.

20.

Is the immune response a friend or foe for viral therapy of glioma?

Okada H, Thorne SH.

Neuro Oncol. 2017 Jul 1;19(7):882-883. doi: 10.1093/neuonc/nox082. No abstract available.

Supplemental Content

Support Center